THE MEDICAL DERMATOLOGY - Summit - CONFERENCE GUIDE - South Beach Symposium
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
PART I THE MEDICAL DERMATOLOGY Summit FEBRUARY 5-7, 2021 CONFERENCE GUIDE DELIVERING THE PREMIER EVENT IN MEDICAL DERMATOLOGY STRAIGHT TO YOU
WELCOME
tter Le
Dear Participants,
Welcome to the first half of the 19th Annual South Beach
Symposium— SBS Part I: The Medical Dermatology
Summit. In so many ways, this year’s conference is our
most transformative and unparalleled yet. To begin,
this marks the first year that SBS will be delivered by
LiVDerm, a leading medical education hub dedicated to
revolutionizing dermatology education. Additionally, for
the first time ever, the Annual South Beach Symposium will
be delivered in two distinct parts: SBS Part I: The Medical
Dermatology Summit (delivered 100% online) and SBS
Part II: The Aesthetic Dermatology Summit (delivered
in-person). These new changes have allowed us to dive
deeper than ever before into the topics that most interest
our broad community of practitioners.
Subsequently, you’ll notice that this event will provide
an expansive view on all the latest updates, trends, and
strategies available in medical dermatology. With frontline
expertise from renowned clinical authorities, participants
will examine a wide array of topics including the impact
of COVID-19 on the dermatology industry, skin of color,
cutaneous oncology, hair restoration, and much more.
The field of medical dermatology is continuously adapting
and clinicians seeking to deliver top-tier, effective care
must always stand ready to integrate the latest knowledge
into practice. Of course, with the added challenges and
complexities of providing care during a global pandemic,
the events of the past year have only increased the pace of
change and advancement. With a steadfast commitment
to provide the most cutting-edge, clinically relevant, and
practically actionable knowledge in dermatology, this event
meets the current moment many clinicians find themselves
in with real solutions.
As we enter a new season, we welcome you and our
entire community of clinicians to adapt and grow with
us as we navigate the many new challenges and exciting
opportunities our industry faces ahead, with the continued
skillful leadership that South Beach Symposium has long
been known for.
On behalf of the entire LiVDerm Team, thank you for your
time and dedication to advancing dermatological wellness.
In Good Health,
The LiVDerm Team
TABLE OF
Contents
Welcome Letter 2-3
Schedule-at-a-Glance - SBS 4–8
Expert Speaker Line-Up - SBS 10 – 12
CE Symposia Listing 13 - 14
Sponsors 15
Accreditation 16 - 25
Association & Media Partners 27
Professional Poster Sessions 28
www.livderm.org 3
SCHEDULE
AT A GLANCE
FRIDAY February 5, 2021
1:45 PM - 1:45 AM Opening Remarks
Mark Nestor, MD, PhD
1:45 PM - 2:00 PM Medical Dermatology in the Age of COVID19
Leon Kircik, MD
2:00 PM - 2:15 PM Telehealth vs. Patient Visits
Mark Kaufmann, MD vs. Linda Stein Gold, MD
2:15 PM - 2:30 PM New Coding for 2021
Mark Kaufmann, MD
2:30 PM - 2:45 PM Breaking News in Skin Cancer
Darrell Rigel, MD
2:45 PM - 3:00 PM Treating Inflammatory Diseases
Amy McMichael, MD
3:00 PM - 3:15 PM Panel Discussion | Q&A
All Faculty
3:15 PM - 3:30 PM Exhibit Break
Hair Restoration for the Dermatologist
Session Director: Glynis R. Ablon, MD, FAAD
3:30 PM - 3:45 PM Keys to Patient Satisfaction + Compassion, Compliance & Results
Glynis R. Ablon, MD, FAAD
3:45 PM - 4:00 PM Etiology and Pathophysiology of Hair Loss
Antonella Tosti, MD
4:00 PM - 4:15 PM Hair Restoration & Diverse Patient Populations - Pearls and Pitfalls
Valerie Callender, MD
4:15 PM - 4:30 PM The Female Patient: Hair Loss Risk Assessment + Testing
Glynis R. Ablon, MD, FAAD
4:30 PM - 4:45 PM The Male Patient with Androgenetic Alopecia
Marc Avram, MD
4:45 PM - 5:00 PM Pros and Cons of Oral Therapy for Androgenetic Alopecia
Marc Avram, MD
5:00 PM - 5:15 PM Effect on Hormones and Hair Loss
Diane Berson, MD
5:15 PM - 5:30 PM Panel Discussion / Q&A
All Faculty
4 www.livderm.org
SCHEDULE
AT A GLANCE
SATURDAY February 6, 2021
Medical Derm Therapeutic Toolkit
Session Director: Leon Kircik, MD
8:00 AM - 8:10 AM Treatments for Wounds
Robert Kirsner, MD
8:10 AM - 8:20 AM Off Label Rxing
Linda Stein Gold, MD
8:20 AM - 8:30 AM Melasma - Step by Step
Seemal Desai, MD
8:30 AM - 8:45 AM Panel Discussion | Q&A
All Faculty
Acne & Rosacea Bootcamp
Session Director: James Q. Del Rosso, DO
8:45 AM - 9:00 AM Top Acne Treatments 2021
James Q. Del Rosso, DO
9:00 AM - 9:15 AM Let the Oral Therapy Debate Begin
Diane Berson, MD
9:15 AM - 9:30 AM Rosacea: What is New
Linda Stein Gold, MD
9:30 AM - 9:45 AM Let the Oral Therapy Debate Begin
Diane Berson, MD
9:45 AM - 10:00 AM Exhibit Break
Diversity in Derm Treatments: Skin of Color Symposium, in partnership with the Skin of Color Society
Session Director: Amy McMichael, MD
Supported by educational grants from Galderma and Incyte.
10:00 AM - 10:15 AM Clinical and Aesthetic Approaches to Melasma
Amy McMichael, MD
10:15 AM - 10:30 AM How to Approach Post-Inflammatory Hyperpigmentation
Valerie Callender, MD
10:30 AM - 10:45 AM Aesthetic Procedure Safety and Nuances
Seemal Desai, MD
10:45 AM - 11:00 AM Panel Discussion | Q&A
All Faculty
www.livderm.org 5
SCHEDULE
AT A GLANCE
SATURDAY February 6, 2021
The Logic in Biologics
Session Director: Leon Kircik, MD
11:00 AM - 11:20 AM Biologics and Psoriasis
Mark Lebwohl, MD
11:20 AM - 11:30 AM Biologics and Hidradenitis Suppurativa
Alice Gottlieb, MD
11:30 AM - 11:40 AM New Dermatologic Uses for Biologics
David Cohen, MD
11:40 AM - 11:50 AM Panel Discussion | Q&A
All Faculty
11:50 AM - 12:00 PM Exhibit Break
CE Symposium:
Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis
Session Director: Linda Stein-Gold, MD, PhD
Faculty: Andrew Alexis, MD and Peter Lio, MD
Supported by educational grants from Incyte Corporation and Pfizer
12:00 PM - 12:15 PM Introduction, Pre-Survey, AD Overview
Linda Stein Gold, MD, Peter Lio, MD
12:15 PM - 12:45 PM New and Emerging Therapies for AD
Linda Stein Gold, MD, Peter Lio, MD, Andrew Alexis, MD
12:45 PM - 12:55 PM Expert Perspectives and Panel Discussion: Interpreting New Advances in Moderate-to-
Severe AD
Linda Stein Gold, MD, Peter Lio, MD, Andrew Alexis, MD
12:55 PM - 1:00 PM Conclusions and Audience Q&A
Linda Stein Gold, MD, Peter Lio, MD, Andrew Alexis, MD
I’ve Been Waiting for This My Whole Derm Life
Session Director: Brian Berman, MD, PhD
1:00 PM - 1:10 PM Innovations in Actinic Keratoses and NMSC therapy
Brian Berman, MD, PhD
1:10 PM - 1:20 PM What is New in Excessive Sweating
Dee Anna Glaser, MD
1:20 PM - 1:30 PM Treatment for Scars
Jill Waibel, MD
1:30 PM - 1:45 PM The Latest in Photodynamic Therapy
Neal Bhatia, MD
1:45 PM - 2:00 PM Panel Discussion | Q&A
All Faculty
2:00 PM - 2:15 PM Active Stretch Session with NASM-Certified Fitness Instructor Aria Aloi
6 www.livderm.org
SCHEDULE
AT A GLANCE
SATURDAY February 6, 2021
Medical Derm Breakthroughs
Session Director: Leon Kircik, MD
2:15 PM - 2:25 PM Pharmaceutical Breakthroughs and Clinical Trials Update
Leon Kircik, MD, FAAD
2:25 PM - 2:35 PM Therapeutic Breakthrough of the New JAK Inhibitors for Alopecia
Antonella Tosti, MD
2:35 PM - 2:45 PM New Approval for Pemphigus Vulgaris
TBA
2:45 PM - 2:55 PM RNAi Formulation for Non-Melanoma Skin Cancer
Mark Nestor, MD, PhD
2:55 PM - 3:05 PM Last Minute Innovations
Leon Kircik, MD
3:05 PM - 3:20 PM Panel Discussion | Q&A
All Faculty
3:20 PM - 3:30 PM Exhibit Break
Radiation Therapies: Let’s Talk Future
Session Director: Brad Glick, DO
3:30 PM - 3:40 PM Understanding the Differences in Radiation Therapies
Mark Nestor, MD, PhD
3:40 PM - 3:50 PM Treating the Lower Extremities
William Roth, MD
3:50 PM - 4:00 PM Superficial Radiation Therapy for Keloids
Brian Berman, MD, PhD
4:00 PM - 4:10 PM A Comprehensive Approach to Grenz Ray Therapy
Brad Glick, DO
4:10 PM - 4:25 PM Panel Discussion | Q&A
All Faculty
4:25 PM - 4:45 PM Exhibit Break
CE Symposium:
Time to Think About Both Skin and Joint Disease: Optimizing the Diagnosis and Management of Psoriatic
Arthritis Through Multidisciplinary, PatientCentered Care
Session Director: Alice Gottlieb, MD
Faculty: Joseph F. Merola, MD, MMSc; Alexis Ogdie, MD, MSCE
Supported by educational grants from Janssen Pharmaceuticals
4:45 PM - 5:05 PM Introduction, Pre-Test, Screening and diagnosing PsA
5:05 PM - 5:30 PM Treatment of PsA
5:30 PM - 5:50 PM Bringing it all Together: Developing a Patient-Centered Approach to Treatment – The
Patient Perspective and Expert Panel Discussion
5:50 PM - 6:00 PM Conclusions, Post-Test, Audience Q & A
www.livderm.org 7
SCHEDULE
AT A GLANCE
SUNDAY February 7, 2021
7:00 AM - 8:00 AM Breakfast Symposium
Gene Expression Profiling in the Management of Cutaneous Squamous Cell Carcinoma
Sherrif F. Ibrahim, MD, PhD
8:00 AM - 9:00 AM PME Symposium: Identifying Appropriate Patients With Advanced CSCC Who May
Bene¬t From Systemic Therapy
Armand Cognetta, MD
9:00 AM - 9:15 AM Exhibit Break
Cutaneous Oncology Symposium
Session Director: Mark Nestor, MD, PhD
9:15 AM - 9:25 AM Innovations in Diagnosis: Precancer to Skin Cancer, Pathology and CPC Cases
Clay Cockerell, MD
9:25 AM - 9:35 AM Cutaneous Oncology Screening and Dermoscopy
David Goldberg, MD
9:35 AM - 9:45 AM Epidemiology and Clinical Presentation of Melanoma
David Goldberg, MD
9:45 AM - 9:55 AM Genetic Approaches to the Prognosis of Melanoma
Darrell Rigel, MD
9:55 AM - 10:05 AM Treatment Approaches & Consensus Guidelines for Melanoma & Non-Melanoma Skin
Cancer
Jose Lutzky, MD
10:05 AM - 10:20 AM Exhibit Break
10:20 AM - 11:05 AM PME Symposium: Perspectives in the Management of Stage IA/IB MF-CTCL: Current
Concepts in Clinical Practice
Lindsay Ackerman, MD, FAAD
11:05 AM - 11:20 AM Exhibit Break
11:20 AM - 11:30 AM Epidemiology and Clinical Presentation of BCC and SCC
David Goldberg, MD
11:30 AM - 11:40 AM Clinical Update: CSCC Treatment
Emily Ruiz, MD
11:40 AM - 11:50 AM Radiation Therapies
Mark Nestor, MD
11:50 AM - 12:00 PM Surgical Innovations
Susan Weinkle, MD
12:00 PM - 12:30 PM Panel Discussion | Q&A
All Faculty
8 www.livderm.org
EXPERT SPEAKER
LINE-UP
CHAIR Mark S. Nestor, MD, PhD
Director, Center for Cosmetic Enhancement
Director, Center for Clinical and Cosmetic Research
Voluntary Professor
Department of Dermatology and Cutaneous Surgery
Department of Surgery, Division of Plastic and Reconstructive Surgery
University of Miami Miller School of Medicine
President, American Cutaneous Oncology Society
Chair, 2021 South Beach Symposium
Aventura, FL
SENIOR PLANNING COMMITTEE
Z. Paul Lorenc, MD, FACS David J. Goldberg, MD, JD
Lorenc Private Practice Aesthetics Medical Director, Skin Laser & Surgery Specialists of NY and NJ
New York, NY Hackensack, NJ
Leon Kircik, MD Michael H. Gold, MD, FAAD
Medical Director Medical Director of Gold Skin Care Center, Advanced Aesthetics
Physicians Skin Care, PLLC Medical Spa
Skin Sciences, PLLC The Laser & Rejuvenation Center, and Tennessee Clinical Research
Center
DermResearch, PLLC
Nashville, TN
Louisville, KY
FACULTY
Glynis R. Ablon, MD, FAAD Andrew F. Alexis, MD, MPH Marc R. Avram, MD
Ablon Skin Institute and Research Chair of the Department of Dermatology Clinical Professor of Dermatology at the
Center at Mount Sinai Morningside and Mount New York Presbyterian Hospital Weill
Manhattan Beach, CA Sinai West Medical College at Cornell Medical
Professor of Dermatology at the Icahn Center
School of Medicine at Mount Sinai New York, NY
New York, NY
Brian Berman, MD, PhD Diane S. Berson, MD Neal Bhatia, MD
Professor Emeritus, Associate Professor Director of Clinical Dermatology
University of Miami Miller School of Weill Cornell Medicine Therapeutics Clinical Research
Medicine New York City, NY San Diego, CA
Miami Beach, FL
10 www.livderm.orgValerie Callender, M Clay Cockerell, MD David E. Cohen, MD, MPH
Medical Director Callender Dermatology Clinical Professor, Dermatology and Charles C. and Dorothea E. Harris
& Cosmetic Center Pathology, UT Southwestern Professor and Vice Chairman for Clinical
Glenn Dale, MD Dallas, TX Affairs Director of Allergic, Occupational,
and Environmental Dermatology
New York University School of Medicine
New York
New York, NY
James Q. Del Rosso, DO Seemal R. Desai, MD, FAAD Dee Anna Glaser, MD
Dermatologist / Research Director Clinical Assistant Professor of Professor and Interim Chair of the
Thomas Dermatology / JDR Dermatology Dermatology, The University of Texas Department of Dermatology at Saint
Research Southwestern Medical Center Louis University School of Medicine, with
Las Vegas, NV Founder & Medical Director, Innovative a Secondary Appointment as Professor of
Dermatology Internal Medicine and Otolaryngology
Plano, TX St. Louis, MO
Brad P. Glick, DO, MPH, FAAD David Goldberg, MD, JD Linda Stein-Gold, MD
Dermatologist Glick Skin Institute- SCA Medical Director, Skin Laser & Surgery Director of Clinical Research Henry Ford
Dermatology Specialists of NY and NJ Health System
Margate, FL Hackensack, NJ Bloomfield Hills, MI
Alice B Gottlieb, MD PhD Leon Kircik MD Mark Kaufmann, MD
Clinical Professor and Medical Director Medical Director Chief Medical Officer Advanced
Dept.of Dermatology Icahn School of Physicians Skin Care, PLLC Dermatology and Cosmetic Surgery
Medicine at Mt. Sinai Skin Sciences, PLLC Bal Harbour, FL
New York, NY DermResearch, PLLC
Louisville, KY
Robert S. Kirsner, MD, PhD Mark Lebwohl, MD Peter A. Lio, MD
Chairman and Harvey Blank Professor, Professor and Dean for Clinical Clinical Assistant Professor of
University of Miami Therapeutics Icahn School of Medicine at Dermatology and Pediatrics
Miami, FL Mount Sinai Northwestern University Feinberg School
New York, NY of Medicine
Chicago, IL
Jose Lutzky, MD Andrea Maderal, MD Amy McMichael, MD
Director, Cutaneous Oncology Services Assistant Professor University of Miami Chair of the Dermatology Department,
Director, Clinical Trials Coordinating Unit Miller School of Medicine Wake Forest Baptist Health
Professor, Department of Medicine, Miami, FL Winston Salem, NC
University of Miami
Miami, FL
Joseph F. Merola, MD Mark S. Nestor, MD, PhD Alexis Ogdie, MD
Associate Professor, Harvard Medical Director, Center for Cosmetic Enhancement Associate Professor of Medicine at
School Brigham and Women’s Director, Center for Clinical and Cosmetic the Hospital of the University of
Hospital Research Pennsylvania
Boston, MA Voluntary Professor Associate Professor of Epidemiology in
Department of Dermatology and Biostatistics and Epidemiology
Cutaneous Surgery Philadelphia, PA
Department of Surgery, Division of Plastic
and Reconstructive Surgery
University of Miami Miller School of
Medicine
President, American Cutaneous Oncology
Society
Chair, 2021 South Beach Symposium
Aventura, FL
www.livderm.org 11Darrell Rigel, MD MS (MBA) William Roth, MD, PA Emily S. Ruiz, MD., MPH
Clinical Professor of Dermatology New Voluntary Clinical Professor of Assistant professor in Dermatology
York University School of Medicine Dermatology U. Miami Department of Harvard Medical School Brigham and
New York, NY Dermatology Women’s Hospital
Boynton Beach, FL Boston, MA
Antonella Tosti, MD Jill Waibel, MD Susan H. Weinkle, MD
Fredric Brandt Endowed Professor Miami Dermatology and Laser Institute Mohs Surgeon/ Cosmetic Dermatologist
of Dermatology Dr. Phillip Frost Subsection Chief of Dermatology Susan H. Weinkle, MD
Department of Dermatology and at Baptist Hospital and the Medical Bradenton, Florida
Cutaneous Surgery University of Miami Director of Miami Cancer Institute’s
Miller School of Medicine Multidisciplinary Skin Cancer Clinic
Miami, FL Clinical Voluntary Assistant Professor at
the University of Miami.
Miami, FL
ONDEMAND
Markus Boos, MD PhD David E. Cohen, MD, MPH Brian Ginsberg, MD
Assistant Professor of Pediatrics Charles C. and Dorothea E. Harris Dermatologist Chelsea Skin & Laser
University of Washington School of Professor and Vice Chairman for Clinical Assistant Clinical Professor in
Medicine Affairs Director of Allergic, Occupational, Dermatology at Mount Sinai Hospital
Seattle, WA and Environmental Dermatology New York, NY
New York University School of Medicine
New York
New York, NY
Andrew Heyman, MD Rajani Katta, MD Jonette Keri, MD PhD
Medical Director of Integrative Medicine Founder Katta Dermatology Associate Professor University of Miami,
George Washington University Bellaire, TX Philip Frost Department of Dermatology
Aldie, VA and Cutaneous Surgery; Dermatology
Service Chief, Miami VA Hospital
Miami, FL
Peter A. Lio, MD Mark S. Nestor, MD, PhD Theodore Rosen. MD
Clinical Assistant Professor of Director, Center for Cosmetic Professor and Vice-Chair, Department
Dermatology and Pediatrics Enhancement of Dermatology Baylor College of
Northwestern University Feinberg School Director, Center for Clinical and Cosmetic Medicine
of Medicine Research Houston, TX
Chicago, IL Voluntary Professor
Department of Dermatology and
Cutaneous Surgery
Department of Surgery, Division of
Plastic and Reconstructive Surgery
Anthony M. Rossi, MD University of Miami Miller School of Sahar Swidan, PharmD, BCPS,
Assistant Attending, Assistant Professor Medicine ABAAHP, FAARFM, FACA
of Dermatology Memorial Sloan President, American Cutaneous Director of Professional Programming
Kettering Cancer Center / Weill Cornell Oncology Society A4M/MMI
Medical College Chair, 2021 South Beach Symposium Ann Arbor, MI
New York, NY Aventura, FL
Gil Yosipovitch, MD
Professor University of Miami
Miami, FL
12 www.livderm.orgCE SYMPOSIAListing
Saturday, February 6, 2021
12:00 PM – 1:00 PM Eastern Time
Clinical Update: Novel Agents for the Long-Term
Management of Moderate-to-Severe Atopic Dermatitis
Chair: Linda Stein-Gold, MD TARGET AUDIENCE
Faculty: Peter A Lio, MD; Alexis F. Andrews, MD, MPH This activity is designed for US-based physicians, nurses and
professional staff members of medical practices specializing
This activity is jointly provided by AKH, Inc. Advancing Knowl- in dermatology as well as allergists, primary care physi-
edge in Healthcare and Tarsus Cardio Inc. dba LiVDERM. cians, nurses, nurse practitioners, physician assistants, and
pharmacists.
EDUCATIONAL GRANT SUPPORT
Multisupported by educational grants from Pfizer Inc. and FACULTY
Incyte Corp. ndrew F. Alexis, MD, MPH
A
Chair of the Department of Dermatology at
PROGRAM OVERVIEW Mount Sinai Morningside and Mount Sinai
The increasing incidence of Atopic dermatitis (AD) and poor West
recognition of the disease in some patient groups is a public Professor of Dermatology at the Icahn
health concern. AD symptoms and its daily management School of Medicine at Mount Sinai
cause significant effects on quality of life for both patients New York, NY
and caregivers. AD is associated with an increase in other
atopic manifestations as well as with serious comorbidities Peter A. Lio, MD
that can greatly affect overall patient health and wellbeing Clinical Assistant Professor of Dermatology
(Silverberg 2015; Simpson 2012; Yu 2016; Zheng 2011). and Pediatrics Northwestern University
Feinberg School of Medicine
Timely and adequate treatment of AD is essential for helping Chicago, IL
to promote better long-term outcomes and quality of life and
may help prevent the development of other atopic conditions Linda Stein-Gold, MD (Symposium
(Leung 2014). However, the treatment of AD is a clinical Chair)
challenge. Patients continue to report treatment dissatisfac- Director of Clinical Research Henry Ford
tion, recurrent flares, and impaired quality of life (Silverberg Health System
2018; Wei 2019). Bloomfield Hills, MI
Targeted immunomodulatory agents, based on recent ACCREDITATION
advances in the understanding of AD pathophysiology, repre- Accreditation may be found on page 20
sent additional options for long-term control, with one agent
that is FDA approved and several others in advanced clinical
development (Kalamaha 2019). Thus, additional education
about current and emerging long-term strategies to AD man-
agement is crucial for their interpretation and application to
clinical practice.
LEARNING OBJECTIVES
• Interpret the efficacy and safety of current non-pharma-
cological and pharmacological treatments for AD and
their limitations in long-term disease management.
• Summarize the mechanisms of action and evidence with
new and emerging targeted immunomodulatory agents
for long-term AD management.
• Develop individualized treatment plans for patients with
moderate-to-severe AD that go beyond just treating
flares and symptoms in order to optimize long-term
control and overall quality of life.
www.livderm.org 13CE SYMPOSIA Listing
Saturday, February 6, 2021
4:45 PM – 6:00 PM Eastern Time
Time to Think About Both Skin and Joint Disease:
Optimizing the Diagnosis and Management of Psoriatic
Arthritis
Chair: Alice B Gottlieb, MD PhD
Faculty: Joseph F. Merola, MD, MMSc; Alexis Ogdie, MD TARGET AUDIENCE
This activity is designed for US-based physicians, nurses and
This activity is jointly provided by AKH, Inc. Advancing Knowl- professional staff members of medical practices specializing
edge in Healthcare and Tarsus Cardio Inc. dba LiVDERM. in dermatology, plastic surgery, cosmetic surgery, rheumatol-
ogy and other dermatologic medical procedures.
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Janssen Pharma- FACULTY
ceuticals Alice B Gottlieb, MD PhD
Clinical Professor and Medical Director
PROGRAM OVERVIEW Dept.of Dermatology Icahn School of
Psoriasis is a chronic and inflammatory skin disease with po- Medicine at Mt. Sinai
tential systemic implications that affects 7.5 million people in New York, NY
the United States (Bhushan 2016; Soleymani 2018) that can
lead to several comorbidities, including psoriatic arthritis, Joseph F. Merola, MD, MMSc
obesity, metabolic syndrome, and cardiovascular disease Associate Professor, Harvard Medical
(Soleymani 2018). School Brigham and Women’s Hospital
Early diagnosis and treatment are crucial in managing PsA, Boston, MA
and clinicians need to understand the impact of both skin
and joint aspects of psoriasis and PsA in order to minimize
impact on patients’ quality of life (QOL). Current methods Alexis Ogdie, MD
to assess disease severity may not be practical to use in Associate Professor of Medicine at the
routine care, contributing to the undertreatment or incorrect Hospital of the University of Pennsylvania
treatment of PsA (Elmets 2019). Due to ongoing suboptimal Associate Professor of Epidemiology in
management of PsA, there is a need to educate clinicians Biostatistics and Epidemiology
that treat patients with PsA on the diagnosis and current Philadelphia, PA
treatment approach, particularly in light of new guidelines
for psoriasis (Elmets 2019) and PsA (Singh 2019). ACCREDITATION
Accreditation may be found on page 22
LEARNING OBJECTIVES
• Identify key clinical features of PsA to improve timely
screening, diagnosis, or referral.
• Utilize practical strategies to evaluate PsA severity that
incorporate both joint and skin manifestation in order to
guide treatment.
• Develop individualized treatment strategies for patients
with PsA based on the efficacy and safety of current and
emerging pharmacotherapies, evidence-based guide-
lines, and patient specific needs and preferences.
14 www.livderm.org19th Annual South Beach Symposium presented by LiVDerm
February 5-7, 2021
Online
ACTIVITY OVERVIEW
At The Medical Dermatology Summit, led by renowned clinical authorities, attendees will gain actionable knowledge on the most relevant topics in medical dermatology
including the impact of COVID-19 on the dermatology industry, cutaneous oncology, hair restoration, and much more all from the safety of their home.
The summit will deliver an interactive educational experience that optimizes all the advantages of virtual education with live-streamed sessions, on-demand content,
faculty Q&A, live engagement, and networking with key industry opinion leaders.
TARGET AUDIENCE
This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology, pediatric dermatology,
plastic surgery, cosmetic surgery and other dermatologic medical procedures.
LEARNING OBJECTIVES
Upon completion of the educational activity, participants should be able to:
• Summarize new and emerging therapies for the treatment of acne.
• Evaluate the efficacy and safety of acne treatments, including the need to appropriately modify therapy and practice antibiotic stewardship.
• Describe recent advances in the treatment of actinic keratosis that have high levels of patient satisfaction, decreased treatment duration, and fewer side-effects.
• List the pathogenic mechanisms of atopic dermatitis.
• Review individualized treatment plans for patients with moderate-to-severe atopic dermatitis based on current guideline recommendations, the safety and efficacy of
new and emerging treatment options, comorbidities, and patients’ quality of life.
• List current and emerging treatment options for alopecia areata.
• Review and compare efficacy and safety of biologic agents, devices, and techniques currently available in hair restoration for androgenic alopecia.
• Define the efficacy and safety of emerging treatment options for hidradenitis suppurativa.
• Review the new and emerging treatment options for hyperhidrosis.
• Summarize new and emerging therapies for the treatment of psoriasis.
• Review the significance of addressing comorbidities as important components of psoriasis therapy.
• Review the clinical presentation of rosacea in order to ensure timely diagnosis.
• Summarize traditional, new and emerging therapies for the treatment of rosacea.
• Define the efficacy and safety of the current and new treatment options for seborrheic keratosis.
• Interpret latest clinical evidence for emerging treatments of keloids.
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon com-
pletion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have questions
about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio
dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 16.5 Interprofessional Continuing Education (IPCE) credit for learning and
change.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 16.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse
16.5 ANCC contact hours
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for
activities planned in accordance with AAPA CME Criteria. This activity is designated for 16.5 AAPA Category 1 CME credits. PAs should only claim credit
commensurate with the extent of their participation.
COMMERCIAL SUPPORT
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer Inc., Sirnaomics, Inc.
16 www.livderm.orgDISCLOSURE
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose
to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter
of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant
financial relationships to disclose.
DISCLOSURES
NAME RELATIONSHIP COMPANY
Glynis Ablon, MD, FAAD N/A Nothing to disclose
Marc Avram, MD N/A Nothing to disclose
Brian Berman, MD, PhD Biofrontera, Ferndale Laboratories, Inc., Galderma Laboratories, L.P.,
GlaxoSmithKline, LEO Pharma - Advisory Board, Medimetriks Pharmaceuticals
Inc., Miragen - Consultant Honoraria, Encore - Consultant, Siranomics - Consultant,
Pierre-Fabre - Consultant, Pfizer - Consultant, Lemonex - Consultant, Novan -
Consultant Honoraria, Novartis Pharmaceuticals Corp. - Advisory Board & Speaker
Honoraria, Sonoma (Oculus Innovative Sciences, Inc.) - Consultant Stock Options,
Sensus - Speaker Consultant Honoraria Investigator, Smith & Nephew - Advisory
Board Honoraria, TopMD - Advisory Board, Ortho Dermatologics/Valeant - Advisory
Board, Cutanea - Advisory Board, Birch BioMed - Advisory Board, Encore Dermatology
- Consultant, Aclaris - Consultant, Aiviva - Consultant, Clark Pharmaceutical, Tigercat
Pharma, Inc, Menlo Therapeutics - Consultant, BMS - Consultant, Pulse - Consultant,
Almirall - Consultant, Mediwound - Consultant
Diane Berson, MD Consultant Aclaris, Allergan, Almirall, Cassiopea, CLN, Crown, Evolus, Ferndale, L'Oreal, Ortho
Derm, Procter and Gamble, Regimen Pro, Revance, Sonoma
Neal Bhatia, MD Consultant Almirall, Biofrontera, Ortho, Sun Pharma
Markus Boos, MD PhD N/A Nothing to disclose
Valerie Callender, MD Consultant Aerolase
Speakers Bureau Ortho Dermatologics
Clay Cockerell, MD Consultant Almirall
David Cohen, MD, MPH Board of Directors Kadmon, Timber, Evommune, Dermira
Consultant Asana, Dermavant, Celgene, Cutanea, Ferndale Laboratories, Ferrer, FSJ, Leo,
Medimetriks, UCB
FIDE. (FIDE receives industry
sponsorship from AbbVie, Almirall,
Amgen, Bausch and Lomb, Bristol-Myers
Squibb, Celgene Dermavant, Dermira,
Janssen, Kyowa Hakko Kirin, LEO, Lilly,
Novartis, Ortho Dermatologics, Pfizer,
Sanofi Genzyme, Sun Pharma, UCB,
Valeant)
James Del Rosso, DO Consultant Almirall, Bausch (Ortho), BioPharmX, Cassiopea, Inc., EPI Health, Galderma,
LeoPharma, Mayne Pharma, Novan, SolGel, Sonoma, Sun Pharma, Vyne Therapeutics
Inc
Contracted Research Almirall, Bausch (Ortho), BioPharmx, Galderma, LeoPharma, Mayne Pharma, Novan,
SolGel, Sun Pharma, Vyne Therapeutics Inc
Speakers Bureau Almirall, Bausch (Ortho), EPI Health, Galderma, LeoPharma, Mayne Pharma, Sun
Pharma, Vyne Therapeutics Inc
Seemal Desai, MD Advisory Board Dermavan Sciences, Foundation for Research & Education of Dermatology
Consultant Galderma Laboratories, Cassiopea SpA, Ortho Dermatologics, SkinCeuticals LLC,
Dermira, Almirall, Scientis Sente Labs, Foamix, Pfizer Inc., Verrica Pharmaceuticals,
Inc, Ferndale, Avita, Gore Range Capital, Incyte Corporation, Bristol Myers Squibb,
UCB
Contracted Research Abbvie, Atacama, Incyte Corporation, Dermavant Sciences, Novan, AOBiome, LLC,
Brickell Biotec
Speakers Bureau Almirall, Ortho Dermatologics
Stock Gore Range Capital
Brian Ginsberg, MD N/A Nothing to disclose
Michael Gold, MD Consultant Aerolase, Alastin, Allergan, Alma Lasers, Almirall, BioFrontera, Clarify MD, Croma,
DefenAge, Dermira, EndyMed, Essence Novel, Galderma, Hugel, IntraDerm, Invasix
/ InMode, Johnson & Johnson, Joylux, Lumenis, Merz, MTF, NanoPass, Neauvia,
Novartis, Pierre Fabre / Glytone, Revision, Sensus, Senté, Skinbetter Science,
Sofregen, Stratpharma, Suneva, Candela, Viviscal, Zimmer
www.livderm.org 17David Goldberg, MD N/A Nothing to disclose
Dee Anna Glaser, MD Consultant Brickell, Candesant, Dermira, Revance, Recross
Contracted Research Allergan, Atacama, Brickell, Dermira, Galderma
Speakers Bureau Allergan, Dermira, Galderma
Brad Glick, DO, MPH, FAAD N/A Nothing to disclose
Alice Gottlieb, MD, PhD Consultant Janssen , Novartis , UCB
Contracted Research Janssen , Novartis and UCB (paid to MT Sinai School of Medicine)
Stock Options XBiotech
Andrew Heyman, MD N/A Nothing to disclose
Rajani Katta, MD Royalty Author of a book for the general public on diet and dermatology
Mark Kaufmann, MD Stock Options Modernizing Medicine, Klara
Jonette Keri, MD, PhD Speakers Bureau Foamix Pharmcueticals
Leon Kircik, MD Advisory Board Aclaris, Allergan, Inc., Almirall, Anacor Pharmaceuticals, Biogen-Idec, Cassiopea, Inc.,
Colbar, Celgene, Cipher, Connetics Corporation, EOS, Exeltis, Ferndale, Laboratories,
Inc., Foamix, Genentech, Inc., Intendis, Innocutis, Isdin, Johnson & Johnson, Nano
Bio, OrthoNeutogena, Promius, Quinnova, SkinMedica, Inc., Stiefel Laboratories,
Inc., Sun Pharma, Valeant Pharmaceuticals Intl, Warner-Chilcott
Consultant Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Cassiopea, Inc.,
Colbar, Cipher, CollaGenex, Connetics Corporation, Exeltis, Foamix, Genentech,
Inc., Intendis, Isdin, Johnson & Johnson, Laboratory Skin Care Inc, LEO, Medical
International Technologies, Merck, Merz, Novartis AG, OrthoNeutrogena, Promius,
PuraCap, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, UCB, Valeant
Pharmaceuticals, ZAGE
Contracted Research Acambis, Allergan, Inc., Amgen, Inc., Anacor Pharmaceuticals, Astellas Pharma
US, Inc., Asubio, Berlex Laboratories (Bayer HealthCare Pharmaceuticals),Biolife,
Biopelle, Boehringer-Ingleheim, Breckinridge Pharma, Celgene, Centocor, Inc.
Cellceutix, Coherus, CollaGenex, Combinatrix, Connetics Corporation, Coria,
Dermavant, Dermira, Dow Pharmaceutical Sciences, Inc., DUSA, Eli Lilly, Exeltis,
Ferndale Laboratories, Inc., Foamix, Genentech, Inc., GlaxoSmithKline, PLC,
Healthpoint, LTD, Idera, Intendis, Johnson & Johnson, LEO, L’Oreal, 3M, Maruho,
Medicis Pharmaceutical Corp., Merck, Nano Bio, Novartis AG, Noven Pharmaceuticals,
Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, Promius, QLT, Inc.
Quinnova, Quatrix, , PharmaDerm, Pfizer, SkinMedica, Inc., Stiefal Laboratories, Inc.,
Sun Pharma, TolerRX, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort
Speakers Bureau Abbott Laboratories, Allergan, Inc., Amgen, Inc., Assos Pharma, Astellas Pharma
US, Inc., Cipher, CollaGenex, Connectics Corporation, Dermik Laboratories, Embil
Pharmaceuticals, Exeltis, Foamix, Genentech, Inc., Innocutix, Innoval, Johnson &
Johnson, LEO, L’Oreal, 3M, Onset, OrthoNeutrogena, PediaPharma, PharmaDerm,
Serono (Merck Serono International SA),SkinMedica, Inc., Stiefel Laboratories, Inc.,
Sun Pharma, Taro, Triax, UCB, Valeant Pharmaceuticals, Intl, Warner-Chilcott,
Stock Johnson & Johnson
Robert Kirsner, MD, PhD N/A Nothing to disclose
Mark Lebwohl, MD Consultant Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc.,
BMD skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics,
Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Evommune, Facilitate
International Dermatologic Education, Foundation for Research and Education in
Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma,
Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono,
Theravance, and Verrica
Contracted Research Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Evommune,
Incyte, Janssen Research & Development, LLC, Leo Pharmaceutucals, Ortho
Dermatologics, Pfizer, and UCB, Inc
Peter Lio, MD Consultant UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals,
AbbVie, Kiniksa, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre, Johnson & Johnson, Level
Ex, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm
Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, Burt's Bees,
Kimberly-Clark
Contracted Research National Eczema Association, AOBiome, Regeneron/Sanofi Genzyme, and AbbVie
Royalties Theraplex: Theraplex AIM OTC moisturizer
Speakers Bureau Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, Galderma, L'Oreal
Stock Options Micreos Altus Labs
18 www.livderm.orgZ. Paul Lorenc, MD, FACS N/A Nothing to disclose
Jose Lutzky, MD N/A Nothing to disclose
Andrea Maderal, MD N/A Nothing to disclose
Amy McMichael, MD Consultant Allergan, Almirall, Bioniz, Cassiopea, Covance, eResearch Technology, Inc., Galderma,
Incyte, Johnson & Johnson, Keranetics, Lilly, Merck & Co., Inc., Pfizer Proctor &
Gamble, Revian, Samumed
Contracted Research Allergan, Cassiopea, Concert Pharmaceuticals, Incyte, Pfizer Proctor & Gamble,
Samumed
Royalties Informa Healthcare, UpToDate
Mark Nestor, MD, PhD N/A Nothing to disclose
Darrell Rigel, MD Consultant Beiersdorf, Inc., Advisory Board Honoraria, Derm Tech International Advisory Board
Honoraria, Castle Biosciences Advisory Board Honoraria, Ferndale Laboratories,
Inc. Consultant Honoraria, Derm Tech International Consultant Honoraria, SciBASE
Consultant Honoraria
Contracted Research Castle Biosciences Investigator
Grants/Research Stock Foamix
Theodore Rosen, MD N/A Nothing to disclose
Anthony Rossi, MD Equipment Donated Caliber ID
William Roth, MD Consultant/advisory board Sensus Healthcare (no compensation)
Contracted Research Sensus Healthcare
Emily Ruiz, MD MPH Consultant Genentech, Regeneron/Sanofi
Contracted Research Merck, Regeneron
Linda Stein Gold, MD Consultant Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall,
BMS, UCB, Sol Gel, Ortho Derm
Contracted Research Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall,
UCB, Sol Gel, Ortho Derm, Novartis, AbbVie
Speakers Bureau Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Ortho
Derm
Sahar Swidan, PharmD Employer Pharmacy Solutions (President & CEO)
Speakers Bureau Amgen, Biohaven
Antonella Tosti, MD Consultant Almirall, Bristol Myers Squibb, DS Laboratories, Leo Pharmaceuticals, Lilly, Monat
Global, P&G, Thirty Madison
Jill Waibel, MD N/A Nothing to disclose
Susan Weinkle, MD Consultant Allergan, Ethicon, Galderma, Merz Aesthetics, Proctor and Gamble, Teoxane, Evolus,
Sinclair, Revance, Almirall
Contracted Research Allergan, Derm Avance, Galderma, Teoxane, Evolus, Sinclair, Revance
Speakers Bureau Allergan, Ethicon, Galderma, Merz Aesthetics
Stock Options Derm Avance
Gil Yosipovitch, MD N/A Nothing to disclose
Dorothy Caputo, MA, N/A Nothing to disclose
BSN, RN - CE Director of
Accreditations
LiVDerm Planners and N/A Nothing to disclose
Reviewers
AKH Planners and Reviewers N/A Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered
a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as
giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or
indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information
for each product for discussion of approved indications, contraindications, and warnings.
www.livderm.org 19Clinical Update: Novel Agents for the Long-Term Management of
Moderate-to-Severe Atopic Dermatitis
February 6, 2021
Online
ACTIVITY OVERVIEW
The increasing incidence of Atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. AD symptoms and its daily
management cause significant effects on quality of life for both patients and caregivers. AD is associated with an increase in other atopic manifestations as well as
with serious comorbidities that can greatly affect overall patient health and wellbeing (Silverberg 2015; Simpson 2012; Yu 2016; Zheng 2011). Timely and adequate
treatment of AD is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions (Leung
2014). However, the treatment of AD is a clinical challenge. Patients continue to report treatment dissatisfaction, recurrent flares, and impaired quality of life (Silverberg
2018; Wei 2019). Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for long-
term control, with one agent that is FDA approved and several others in advanced clinical development (Kalamaha 2019). Thus, additional education about current and
emerging long-term strategies to AD management is crucial for their interpretation and application to clinical practice.
TARGET AUDIENCE
This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology as well as allergists,
primary care physician, nurses, nurse practitioners, physician assistants and pharmacists.
LEARNING OBJECTIVES
Upon completion of the educational activity, participants should be able to:
• Interpret the efficacy and safety of current non-pharmacological and pharmacological treatments for AD and their limitations in long-term disease management.
• Summarize the mechanisms of action and evidence with new and emerging targeted immunomodulatory agents for long-term AD management
• Develop individualized treatment plans for patients with moderate-to-severe AD that go beyond just treating flares and symptoms in order to optimize long-term
control and overall quality of life
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon
completion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have
questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio
dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and
change.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse
1 ANCC contact hours
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for
activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit
commensurate with the extent of their participation.
Commercial Support
This activity is supported by educational grants from Incyte Corporation, Pfizer Inc.
DISCLOSURE
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose
to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter
of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant
financial relationships to disclose.
20 www.livderm.orgDISCLOSURE
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose
to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of
this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant
DISCLOSURES
NAME RELATIONSHIP COMPANY
Andrew Alexis, MD Consultant Leo, Novartis, Menlo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Unilever, Beiersdorf,
Valeant, L’Oreal, BMS, Menlo, Scientis, Bausch health , UCB, Foamix , Cassiopea, Arcutis, Janssen,
Allergan, Almirall, Abbvie, Sol-Gel (Self); Pfizer, Sanofi-Regeneron (Spouse/partner)
Contracted Research Leo, Novartis, Almirall, Bristol-Myers-Squibb, Celgene, Menlo, Galderma, Valeant (Bausch Health),
Cara, Arcutis
Peter Lio, MD Consultant UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie,
Kiniksa, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre, Johnson & Johnson, Level Ex, Unilever, Menlo
Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma,
Verrica, Arbonne, Amyris, Bodewell, Burt's Bees, Kimberly-Clark
Contracted Research National Eczema Association, AOBiome, Regeneron/Sanofi Genzyme, and AbbVie
Royalties Theraplex: Theraplex AIM OTC moisturizer
Speakers Bureau Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, Galderma, L'Oreal
Stock Options Micreos Altus Labs
Linda Stein Gold, MD Consultant Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall, BMS, UCB, Sol
Gel, Ortho Derm
Contracted Research Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall, UCB, Sol Gel,
Ortho Derm, Novartis, AbbVie
Speakers Bureau Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Ortho Derm
Dorothy Caputo, MA, N/A Nothing to disclose
BSN, RN - CE Director of
Accreditations
LiVDerm Planners and N/A Nothing to disclose
Reviewers
AKH Planners and N/A Nothing to disclose
Reviewers
All of the relevant financial relationships listed for these individuals have been mitigated.
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered
a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as
giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or
indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information
for each product for discussion of approved indications, contraindications, and warnings.
www.livderm.org 21Time to Think About Both Skin and Joint Disease: Optimizing
the Diagnosis and Management of Psoriatic Arthritis Through
Multidisciplinary, Patient-Centered Care
February 6, 2021
Online
ACTIVITY OVERVIEW
Psoriasis is a chronic and inflammatory skin disease with potential systemic implications that affects 7.5 million people in the United States (Bhushan 2016; Soleymani
2018) that can lead to several comorbidities, including psoriatic arthritis, obesity, metabolic syndrome, and cardiovascular disease (Soleymani 2018). Early diagnosis
and treatment are crucial in managing PsA, and clinicians need to understand the impact of both skin and joint aspects of psoriasis and PsA in order to minimize impact
on patients’ quality of life (QOL). Current methods to assess disease severity may not be practical to use in routine care, contributing to the undertreatment or incorrect
treatment of PsA (Elmets 2019). Due to ongoing suboptimal management of PsA, there is a need to educate clinicians that treat patients with PsA on the diagnosis and
current treatment approach, particularly in light of new guidelines for psoriasis (Elmets 2019) and PsA (Singh 2019).
TARGET AUDIENCE
This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology, plastic surgery,
cosmetic surgery, rheumatology and other dermatologic medical procedures.
LEARNING OBJECTIVES
Upon completion of the educational activity, participants should be able to:
• Identify key clinical features of PsA in order to improve timely screening, diagnosis, or referral
• Utilize practical strategies to evaluate PsA severity that incorporate both joint and skin manifestation in order to guide treatment
• Develop individualized treatment strategies for patients with PsA based on the efficacy and safety of current and emerging pharmacotherapies, evidence-based
guidelines, and patient specific needs and preferences
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon
completion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have
questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio
dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and
change.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse
1.25 ANCC contact hours
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for
activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit
commensurate with the extent of their participation.
COMMERCIAL SUPPORT
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
22 www.livderm.orgDISCLOSURE
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose
to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter
of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant
financial relationships to disclose.
Disclosures
NAME RELATIONSHIP COMPANY
Alice Gottlieb, MD, PhD Consultant Janssen , Novartis , UCB
Contracted Research Janssen , Novartis and UCB (paid to MT Sinai School of Medicine)
Stock Options XBiotech
Joseph Merola, MD, MMSc Consultant Abbvie, Amgen, Bayer, Eli Lilly, Novartis, Janssen, UCB, Celgene,
Sanofi-Regeneron, Biogen, Pfizer, and BMS
Alexis Ogdie-Beatty, MD Consulting/Advisory Boards Abbvie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer,
UCB
Grants Pfizer to Penn, Novartis to Penn, Amgen to Forward/NDB
Royalties Novartis to my husband
Other Funding NIAMS, Rheumatology Research Foundation, National Psoriasis Foundation,
University of Pennsylvania
Dorothy Caputo, MA, BSN, RN - CE Direc- N/A Nothing to disclose
tor of Accreditations
LiVDerm Planners and Reviewers N/A Nothing to disclose
AKH Planners and Reviewers N/A Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered
a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as
giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or
indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information
for each product for discussion of approved indications, contraindications, and warnings.
www.livderm.org 23Diversity in Derm Treatments: Skin of Color
February 6, 2021
Online
ACTIVITY OVERVIEW
There are gaps in dermatologic care today concerning patients with skin of color (SOC) that need to be addressed through education and putting new knowledge into
practice. Patients with SOC can be disproportionately affected by dermatologic conditions such as melasma, acne, rosacea, and hyperpigmentation. Even children with SOC
can be more susceptible or have a greater disease burden, especially with conditions such as acne, vitiligo, atopic dermatitis, keloids, pityriasis alba, and traction alopecia.
It is important that clinicians are not only aware of these disparities across multiple disease states, but that they are aware of changes to practice that need to be made.
The Skin of Color Symposia is designed to address these gaps in dermatologic care for SOC patients by reviewing skin conditions prevalent in SOC patients or those which
disproportionately burden SOC patients. Participants will gain education needed to better treat these conditions and modify current practices to accommodate the needs of
patients with darker pigmented skin.
TARGET AUDIENCE
This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology, plastic surgery,
cosmetic surgery and other dermatologic medical procedures.
LEARNING OBJECTIVES
Upon completion of the educational activity, participants should be able to:
• Identify the challenges in treating SOC patients for melasma and the considerations that must be made in designing a treatment plan
• Review the clinical and aesthetic treatments available for melasma patients
• List current and emerging vitiligo treatments for pediatric patients.
• Describe the impact of vitiligo in patients with darker pigmented skin and implications for managing vitiligo in this setting.
• Classify current and emerging treatments for acne patients, including recommendations for treating the pediatric patient population.
• Summarize the challenges associated with different acne and rosacea treatment options for patients with skin of color
• Prioritize how to diagnose acne and rosacea in patients with skin of color.
• Articulate current and emerging AD treatments for pediatric patients.
• Recognize the ways in which pediatric AD patients with SOC are affected in terms of managing their condition.
• Distinguish the prevalence of keloids in the SOC population
• Recall conventional treatment options for pediatric keloid patients
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon
completion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have
questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio
dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and
change.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse
1 ANCC contact hours
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for
activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit
commensurate with the extent of their participation.
24 www.livderm.orgYou can also read
